PIPC has submitted another correspondence to the Minnesota PDAB urging the board to pause its work and work with patients and people with disabilities to make sure they are put first when it comes to decisions that impact treatment affordability.
At the April, 2026 meeting, the Minnesota Prescription Drug Affordability Board had the opportunity to learn from the results of a patient-led survey related to the affordability of medications. During the conversation, the board indicated that it was not positioned to address patient out-of-pocket costs. PIPC has not received a response to its letter in September 2025 providing the PDAB with information on the laws and regulations governing the use of discriminatory value assessments.
Therefore, PIPC provided a letter to the PDAB urging it "to pause its work and to collaborate with patients and people with disabilities on a process that is transparent, includes their meaningful engagement, and safeguards against discrimination in a manner that is compliant with federal laws against use of measures that devalue disabled lives.”
Therefore, PIPC provided a letter to the PDAB urging it "to pause its work and to collaborate with patients and people with disabilities on a process that is transparent, includes their meaningful engagement, and safeguards against discrimination in a manner that is compliant with federal laws against use of measures that devalue disabled lives.”
| pipc_mn_may_2026.pdf |
